Inflammation

SAN DIEGO — Managing systemic inflammation is critical to reducing cardiovascular and pulmonary outcomes in patients with rheumatoid arthritis, according to a presenter at the 2024 Congress of Clinical Rheumatology West.

The FDA has granted approval to dupilumab for treating adults with poorly controlled COPD with type 2 inflammation, according to a manufacturer-issued press release.

Rocatinlimab exhibited promising results in the phase 3 ROCKET HORIZON trial for the treatment of moderate to severe atopic dermatitis, Kyowa Kirin announced in a press release.

As a dentist, I believe it is crucial to highlight the growing evidence linking periodontal health with systemic conditions, particularly respiratory diseases.

For nearly 2 decades, George L. Bakris, MD, was a pillar of the Cardiometabolic Health Congress, sharing his expertise, passion and unwavering dedication to advancing cardiometabolic health.

Patients with different asthma severity regularly used a home device for measuring fractional exhaled nitric oxide for 12 weeks as part of their asthma management strategies, according to a poster presentation here.

Dupilumab’s impact on exacerbation rate and lung function in adults with COPD and type 2 inflammation did not differ based on BODE index score, according to a poster presented at the European Respiratory Society International Congress.

Patients with asthma on dupilumab saw reduced airway inflammation and mucus plugging beginning at 4 weeks with steady improvements through 24 weeks, according to a study presented at the European Respiratory Society International Congress.

At 52 weeks, adults with moderate/severe COPD and type 2 inflammation receiving dupilumab vs. placebo showed more improved symptom scores, according to a poster presented at the European Respiratory Society International Congress.

A clinical scale was validated for early detection of infections at the exit site of central venous catheters for hemodialysis in patients with kidney disease, according to a study.